146 related articles for article (PubMed ID: 12806588)
1. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
Ruilope LM; Segura J; Schiffrin EL
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):74-9. PubMed ID: 12806588
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED; Preddie DC
Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
[TBL] [Abstract][Full Text] [Related]
5. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
7. [Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].
Stern N; Grossman E; ; ; ;
Harefuah; 2003 Apr; 142(4):309-11, 315. PubMed ID: 12754885
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Johnston CI
Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber MA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
Weber MA
Rev Cardiovasc Med; 2002; 3(4):183-91. PubMed ID: 12556752
[TBL] [Abstract][Full Text] [Related]
11. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
13. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
Abassi Z; Armaly Z; Nakhoul F; Hoffman A
Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
[TBL] [Abstract][Full Text] [Related]
14. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
Coyle JD; Gardner SF; White CM
Ann Pharmacother; 2004 Oct; 38(10):1731-8. PubMed ID: 15353571
[TBL] [Abstract][Full Text] [Related]
15. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
16. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
[TBL] [Abstract][Full Text] [Related]
17. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B; Gleim G; Panish J
Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
[TBL] [Abstract][Full Text] [Related]
18. ACE-I and ARBs in early diabetic nephropathy.
Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy.
Deedwania PC
Cardiol Clin; 2005 May; 23(2):139-52. PubMed ID: 15694743
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
